

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
If approved, DLP-160 (6-12 month Naltrexone Implant) is expected to offer a major advancement in the treatment of opioid use disorder by improving medication adherence and reducing relapses.
Lead Product(s): Naltrexone
Therapeutic Area: Psychiatry/Psychology Product Name: DLP-160
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2022
Details:
Proceeds from the financing will be used for the advancement of the company’s tizanidine implant product (DLP-208) for moderate-severe spasticity. DLP-208 can provide sustained therapy for several months, while only requiring a 10-minute procedure in an outpatient setting.
Lead Product(s): Tizanidine HCl
Therapeutic Area: Musculoskeletal Product Name: DLP-208
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Funding November 16, 2021